Skip to content

Study · In vitro (cells) · 2022

6 results

Evaluation of SS-31 as a Potential Strategy for Tendinopathy Treatment: An In Vitro Model.

Zhang X, Zhang Y, Zhang M, Nakagawa Y, Caballo CB, Szeto HH, Deng XH, Rodeo SA

The American journal of sports medicine21 Jul 2022Cited by 12 (Europe PMC)

PMID35862638 (opens in a new tab)DOI10.1177/03635465221107943 (opens in a new tab)PepBankPUB-35862638
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In human degenerative tenocytes, SS‑31 treatment decreased the cell fraction with depolarized mitochondria.

    In plain wordsIn lab-grown human tendon cells, SS‑31 reduced the share of cells with damaged mitochondria.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseFraction of cells with depolarized mitochondria
    Study

    humann = 9

    primary human tenocytes from degenerative supraspinatus tendon
    Comparator
    Untreated degenerative tenocytes
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    1 µM · 72 hoursAs given in this study (human).

    Source sentences

    Summary
    followed by a decrease after SS-31 treatment (P = .018).
    1 context sentence
    Summary · context
    Tenocytes were cultured, used at passage 1, and assigned to 4 groups: healthy tenocytes, healthy tenocytes with 1μM SS-31 treatment for 72 hours, degenerative tenocytes, and degenerative tenocytes with 1μM SS-31 treatment for 72 hours.
  2. 02LabIn vitro (cells)Mechanism

    In human degenerative tenocytes, SS‑31 treatment improved the morphological changes in mitochondria seen by electron microscopy.

    In plain wordsIn lab-grown human tendon cells, SS‑31 improved the shape and number of mitochondria.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMitochondrial morphology
    Study

    humann = 9

    primary human tenocytes from degenerative supraspinatus tendon
    Comparator
    Untreated degenerative tenocytes
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    1 µM · 72 hoursAs given in this study (human).

    Source sentences

    Summary
    with improvement after SS-31 treatment.
    1 context sentence
    Summary · context
    Tenocytes were cultured, used at passage 1, and assigned to 4 groups: healthy tenocytes, healthy tenocytes with 1μM SS-31 treatment for 72 hours, degenerative tenocytes, and degenerative tenocytes with 1μM SS-31 treatment for 72 hours.
  3. 03LabIn vitro (cells)Mechanism

    In human degenerative tenocytes, SS‑31 treatment increased superoxide dismutase activity.

    In plain wordsIn lab-grown human tendon cells, SS‑31 raised the activity of an antioxidant enzyme.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseSuperoxide dismutase activity
    Study

    humann = 9

    primary human tenocytes from degenerative supraspinatus tendon
    Comparator
    Untreated degenerative tenocytes
    Outcome group
    Mitochondrial function · Musculoskeletal
    Studied dose
    1 µM · 72 hoursAs given in this study (human).

    Source sentences

    Summary
    which then increased after SS-31 treatment (P = .012).
    1 context sentence
    Summary · context
    Tenocytes were cultured, used at passage 1, and assigned to 4 groups: healthy tenocytes, healthy tenocytes with 1μM SS-31 treatment for 72 hours, degenerative tenocytes, and degenerative tenocytes with 1μM SS-31 treatment for 72 hours.
  4. 04LabIn vitro (cells)Mechanism

    In human degenerative tenocytes, SS‑31 reduced the upregulated gene expression of matrix metalloproteinase-1.

    In plain wordsIn lab-grown human tendon cells, SS‑31 lowered activity of a gene linked to matrix remodeling.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseMMP-1 gene expression
    Study

    humann = 9

    primary human tenocytes from degenerative supraspinatus tendon
    Comparator
    Untreated degenerative tenocytes
    Outcome group
    Tendon and ligament healing · Musculoskeletal
    Studied dose
    1 µM · 72 hoursAs given in this study (human).

    Source sentences

    Summary
    The gene expression of matrix metalloproteinase-1 (matrix remodeling, P = .029) and fatty acid-binding protein 4 (fatty infiltration, P = .046) was significantly upregulated in the degenerative tenocytes and reduced by SS-31 treatment (P = .048; P = .007).
    1 context sentence
    Summary · context
    Tenocytes were cultured, used at passage 1, and assigned to 4 groups: healthy tenocytes, healthy tenocytes with 1μM SS-31 treatment for 72 hours, degenerative tenocytes, and degenerative tenocytes with 1μM SS-31 treatment for 72 hours.
  5. 05LabIn vitro (cells)Mechanism

    In human degenerative tenocytes, SS‑31 reduced the upregulated gene expression of fatty acid-binding protein 4.

    In plain wordsIn lab-grown human tendon cells, SS‑31 lowered activity of a gene linked to fat infiltration.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseFABP4 gene expression
    Study

    humann = 9

    primary human tenocytes from degenerative supraspinatus tendon
    Comparator
    Untreated degenerative tenocytes
    Outcome group
    Tendon and ligament healing · Musculoskeletal
    Studied dose
    1 µM · 72 hoursAs given in this study (human).

    Source sentences

    Summary
    The gene expression of matrix metalloproteinase-1 (matrix remodeling, P = .029) and fatty acid-binding protein 4 (fatty infiltration, P = .046) was significantly upregulated in the degenerative tenocytes and reduced by SS-31 treatment (P = .048; P = .007).
    1 context sentence
    Summary · context
    Tenocytes were cultured, used at passage 1, and assigned to 4 groups: healthy tenocytes, healthy tenocytes with 1μM SS-31 treatment for 72 hours, degenerative tenocytes, and degenerative tenocytes with 1μM SS-31 treatment for 72 hours.
  6. 06LabIn vitro (cells)Efficacy outcome

    In human degenerative tenocytes, cell viability showed a small improvement after SS‑31 treatment.

    In plain wordsIn lab-grown human tendon cells, SS‑31 gave a small improvement in cell survival.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseCell viability
    Study

    humann = 9

    primary human tenocytes from degenerative supraspinatus tendon
    Comparator
    Untreated degenerative tenocytes
    Outcome group
    Tendon and ligament healing · Musculoskeletal
    Studied dose
    1 µM · 72 hoursAs given in this study (human).

    Source sentences

    Summary
    with small improvement after treatment with SS-31.
    1 context sentence
    Summary · context
    Tenocytes were cultured, used at passage 1, and assigned to 4 groups: healthy tenocytes, healthy tenocytes with 1μM SS-31 treatment for 72 hours, degenerative tenocytes, and degenerative tenocytes with 1μM SS-31 treatment for 72 hours.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.